Publications

Suh M, Movva N, Bylsma LC, Fryzek JP, Nelson CB. 2022. A systematic literature review of the burden of respiratory syncytial virus disease and health care utilization among United States infants younger than 1 year. J Infect Dis 226(Suppl 2):S195–S212; doi: 10.1093/infdis/jiac201. PMID: 35968876.

Suh M, Movva N, Jiang X, Reichert H, Bylsma LC, Fryzek JP, Nelson CB. 2022. Respiratory syncytial virus burden and healthcare utilization in United States infants, <1 year of age: Study of nationally representative databases, 2011–2019. J Infect Dis 226(Suppl 2):S184–S194; doi: 10.1093/infdis/jiac155. PMID: 35968879.

Movva N, Suh M, Reichert H, Hitze B, Sendak MP, Wolf Z, et al. 2022. Respiratory syncytial virus during the COVID-19 pandemic compared to historic levels: A retrospective cohort study of a health system. J Infect Dis 226(Suppl 2):S175–S183; doi: 10.1093/infdis/jiac220. PMID: 35968868.

Suh M, Movva N, Jiang X, Bylsma LC, Reichert H, Fryzek JP, Nelson CB. 2022. Respiratory syncytial virus (RSV) is the leading cause of United States infant hospitalizations 2009–2019: A study of the National (Nationwide) Inpatient Sample. J Infect Dis 226(Suppl 2):S154–S163; doi: 10.1093/infdis/jiac120. PMID: 35968878.

Fergie J, Suh M, Jiang X, Fryzek JP, Gonzales T. 2022. Respiratory syncytial virus and all-cause bronchiolitis hospitalizations among preterm infants using the Pediatric Health Information System (PHIS). J Infect Dis 225(7):1197-1204; doi: 10.1093/infdis/jiaa435.

Rankin DA, Haddadin Z, Lipworth L, Stahl AL, Fryzek J, Suh M, et al. 2022. Comparison of clinical presentations and burden of respiratory syncytial virus in infants across three distinct healthcare settings in Davidson County, Tennessee. Therapeut Adv Infect Dis 9(July 18):20499361221112171; doi: 10.1177/20499361221112171. PMID: 35875809.

Jensen IS, Wu E, Cyr PL, Claussen M, Winkler T, Salahuddin K, Prats J, et al. 2022. Cost-consequence analysis of using cangrelor in high angiographic risk percutaneous coronary intervention patients: A US hospital perspective. Am J Cardiovasc Drugs 22(1):93-104; doi: 10.1007/s40256-021-00491-9. PMID: 34331235.

Alexander AW, Jensen IJ, Hathaway J, Srivastava K, Cyr PL, Sidonio RF, Batt K. 2022. Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements. J Manag Care Spec Pharm 28(5):518-527; doi: 10.18553/jmcp.2022.21197. PMID: 35343812.

Sacks NC, Healey BE, Raza S, Cyr PL, Boerner G, Sheshadri A. 2022. The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States. Blood Adv 6(5):1566–1576.

Sacks NC, Healey BE, Raza S, Cyr PL, Boerner G, Sheshadri A. 2022. The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States. Blood Adv 6(5):1566–1576; doi: 10.1182/bloodadvances.2021004364. PMID: 34807973.